Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PG 201

Drug Profile

PG 201

Alternative Names: Layla; PG201

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroMed Co Ltd
  • Developer PMG Pharm Co Ltd
  • Class Antirheumatics; Phytotherapies
  • Mechanism of Action Cytokine modulators; Interleukin 1 beta inhibitors; Matrix metalloproteinase inhibitors; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 08 May 2014 PMG initiates enrolment in a phase IV LAYLA_P4_NB trial for Osteoarthritis in South Korea (NCT02049606)
  • 01 Sep 2013 PMG Pharm completes a phase IV LAYLA-P4 trial in Osteoarthritis (NCT01768468)
  • 01 Dec 2012 Launched for Osteoarthritis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top